Loading…
Celanese Corporation
NYSE: CE Materials Chemicals 🔎 Screen
$5.1B
Market Cap
8.7
P/E
6.14
PEG
4.9%
ROCE
-22.5%
ROE
2.89
D/E
8.7%
OPM
-33.4%
% from 52W High
36
α RS
⚖️ Compare 🔒 Generate Report 🔒 Research Packet 📚 Guides
🌏 Global Investor Returns
Currency-adjusted total returns for CE including FX impact
🌏
Click 🌏 Returns tab to load data
📈 Price History
Ratio Health
Excellent
Good
Average
Poor
By Category
📊 Sector Averages
About

Celanese Corporation produces and sells engineered polymers worldwide. It operates through Engineered Materials and Acetyl Chain segments. The company offers ethylene acrylic elastomers, ethylene vinyl acetate pharmaceutical grade copolymers, liquid crystal polymers, long-fiber reinforced thermoplastics, nylon and polypropylene compounds and formulations, polyoxymethylene, ultra-high molecular weight polyethylene, and thermoplastic elastomers, polyesters, and vulcanizates for use in appliance, automotive, construction, consumer apparel, consumer electronics, electrical, energy storage, filtration equipment, industrial, medical, and telecommunication applications. It also provides acetic acid and anhydride, acetate flakes and tows, butyl acetates, emulsion polymers, ethyl acetates, ethylene vinyl acetate resins and compounds, formaldehydes, redispersible powders, and vinyl acetate monomers for use in adhesives, automotive parts, coatings, consumer goods, external thermal insulation composite systems, films, filtration, flexible packaging, food and beverage, food packaging, inks, lamination, lubricants, paints, paper finishing, pharmaceuticals, plasticizers, plasters and renders, solvents, textiles, and tiling applications. The company offers its products under the Amcel, AOPlus, Ateva, Avicor, Celanese, Celanex, Celanyl, Celcon, Celstran, Celvolit, Clarifoil, Crastin, Dur-O-Set, Dytron, ECOMID, EcoVAE, Elotex, Factor, Flexbond, Forprene, FRIANYL, Fortron, Geolast, GHR, GUR, Hostaform, Hytrel, Laprene, Melinex, MetaLX, Mowilith, MT, Mylar, NILAMID, Nylfor, OmniLon, Pibifor, Pibiter, Polifor, Resyn, Rynite, Santoprene, SlideX, Sofprene, Sofpur, Talcoprene, Tarnoform, Tecnoprene, TufCOR, Tynex, Vamac, VAntage, Vectra, Vinac, Vinamul, VitalDose, Zenite, and Zytel brands. It sells its products directly to customers and through distributors; and original equipment manufacturers and suppliers. It has a strategic partnership with VIGOR Precision Ltd. Celanese Corporation was founded in 1912 and is headquartered in Irving, Texas.

Key Ratios Snapshot
📈 Growth Pattern
📊 Quick Scorecard
Loading…
⭐ Superinvestors Holding CE
View All Superinvestors →
Manager Shares Value % of Fund Period
Steve Cohen Point72 Asset Management 534.3K $35.1M 0.05% Mar 2026
Jim Simons Renaissance Technologies LLC 28.5K $1.9M 0.00% Mar 2026

SEC Form 13F data. 45-day lag from quarter end.

🔒
Premium Feature
AI-generated 10-section company profile — business model, financials, strengths, risks & management quality
Upgrade to Premium
Already a member? Log in
📐
3-Statement Financial Model
Bear / Base / Bull projections · DCF fair value · Reverse-DCF
Open Model →
🎙 Management Tone Cautious ~ Volatile 4 quarters Full tone analysis in Intelligence →
📊 MIXED Celanese guides $3 EPS in H2 2026 amid supply chain disruptions.
Revenue & Profitability
Celanese reported first quarter 2026 results and provided guidance for the second half of 2026 at $3 per share EPS. The company expects EBITDA growth of a few hundred million this year. Key financial impacts include a $50 million absorption hit in Engineered Materials in the second half, a $30 million cost savings from nylon initiatives with about one-third hitting in 2026, and $15 million of turnaround expense in Q2. Working capital is expected to be roughly flat for the year, with prior assumptions of $100 million source from inventory reduction.
Outlook
Management views the current demand environment as low at the end-use level, with supply chain disruptions in Q2 expected to unwind by the end of the quarter. The second-half guidance assumes a moderation in volumes and margins, but the company is positioned to capture upside if conditions persist. Concerns about demand destruction from high feedstock prices were also noted.
Growth Drivers
Growth in the Acetyl Chain is driven by downstream vinyl emulsions and redispersible powders, with opportunities for switching from oil-based systems. In Engineered Materials, growth is targeted in sub-segments such as medical, electronics, data centers, and high-performance athletic wear. The nylon 6,6 business is being restructured to optimize polymer make vs. buy, aiming for $30 million in savings.
Balance Sheet & CapEx
Not discussed in this earnings call.
Margins
Engineered Materials' EBITDA margin has moved from low teens to consistently above 20%. In the Acetyl Chain, margins improved in Q2 due to supply chain disruptions but are expected to moderate. Price increases in Engineered Materials are being implemented to offset rising raw material costs, with full materialization expected in Q3.
Key Risks
Management flagged potential demand disruption from high inflation and feedstock prices, pre-buying by Engineered Materials customers, and uncertainty in the timing of supply chain normalization. Raw material sourcing issues, particularly at Ibn Sina due to shipping constraints, were also mentioned. The current M&A environment has been negatively impacted by geopolitical events.
Generated by AI · Q1 2026 results · Not investment advice
🔒
Free Account Required

Create a free Finmagine account to access Finmagine™ Scorecard.

See how this company scores across 5 dimensions — Financial Health, Growth Prospects, Competitive Position, Management Quality, and Valuation — powered by 30+ computed ratios.

Create Free AccountLog In
🔒
Premium Feature

Upgrade to Finmagine Premium to unlock Ask AI.

Get 25 expert AI analysis templates — Business KPIs, Comprehensive, Forensic Governance, Peer Comparison, Risk-Reward, Full Research Report, IPO Decoder, Red Flag Detector, and more — ready to paste into ChatGPT, Claude, Gemini, or Perplexity.

Upgrade to PremiumCreate Free Account
🔒
Premium Feature

Upgrade to Finmagine Premium to unlock Peer Comparison.

Compare this company side-by-side against its sector peers with financial metrics, ratio benchmarking, and relative performance across all key dimensions.

Upgrade to PremiumCreate Free Account
✓ 📞 Earnings Call Transcripts (5 quarters) submit a missing quarter
🔍
🔎 See cross-company document search → ?
📞 Earnings Call Transcripts (5)
Q2 2026 Q2 2026 2026-08-05
Operational resilience and strategic focus on high-margin EM sub-segments drove strong Q2 results, with cost actions and divestitures supporting deleveraging and future growth. Guidance remains steady despite inventory absorption and raw material volatility.
Q1 2026 Q1 2026 2026-05-06
Q1 saw strong asset utilization and flexible operations amid weak demand and supply chain disruptions. H2 guidance assumes moderate recovery as supply chains normalize, with upside if current conditions persist. Strategic cost actions and targeted growth in Engineered Materials continue.
Q4 2025 Q4 2025 2026-02-18
Cash generation and cost reduction remain top priorities, with $650M–$750M free cash flow targeted for 2026. Engineered Materials is expected to drive growth, while Acetyl Chain faces margin pressure from overcapacity, especially in China. Divestitures and operational efficiencies support deleveraging.
Q3 2025 Q3 2025 2025-11-07
Priorities for 2026 are cost improvements, cash flow, and top-line growth, with $1-$2 EPS uplift expected even if demand stays flat. Free cash flow is guided at $700M–$800M, and portfolio optimization continues with divestitures and cost actions.
Q2 2025 Q2 2025 2025-08-12
Order books weakened in June and July, with demand softness in China automotive, European EM, and Western Hemisphere acetyls. Q3 EPS guidance is $1.25, with a $2 per share target achievable through cost actions and business model execution, though timing may be delayed if demand remains weak.
🔒
Premium Feature

Upgrade to Finmagine Premium to unlock Catalyst Timeline.

Every result, order win, insider trade, ECS update, earnings-call, and SEC announcement for this company — in one chronological lane.

Upgrade to PremiumCreate Free Account
🔒
Premium Feature

Upgrade to Finmagine Premium to unlock Full Report.

Read the complete Finmagine™ investment research report — comprehensive fundamental analysis, business model assessment, competitive positioning, and investment recommendation.

Upgrade to PremiumCreate Free Account

📊 Analysis Methodology

This comprehensive investment analysis was conducted using The Finmagine™ Stock Analysis & Ranking Methodology, a proprietary framework that systematically evaluates stocks across five critical dimensions: Financial Health, Growth Prospects, Competitive Positioning, Management Quality, and Valuation.

🎯
Discover Our Proven Investment Framework Learn how we analyze and rank stocks using advanced quantitative models, multi-dimensional scoring systems, and dynamic discriminatory ranking techniques that have guided successful investment decisions across market cycles.
📊 Explore The Finmagine™ Methodology

A comprehensive, bias-free framework for analyzing and ranking stocks by Financial Strength, Growth Potential, Competitive Edge, Management Quality, and Value.

Financial Model
Projections are built from each company's audited annual financials (Income Statement, Balance Sheet, Cash Flow) over the last 5 fiscal years. Forward assumptions — revenue growth %, EBITDA margin, D&A (USD millions), interest expense, tax rate, and capex — are AI-generated using historical context and refreshed twice a year: after the December results season and after the September/Q4 results season.

DCF Valuation
Fair Value = Σ(FCFt / (1+WACC)t) + Terminal Value. Terminal Value uses the Gordon Growth Model: FCF5 × (1+g) / (WACC−g). Default WACC: 10% (US risk-free ~4.5%, equity risk premium ~5.5%). Default terminal growth: 3% (long-run US nominal GDP proxy).

CAGR Tracker
Expected 5-year CAGR = (DCF Fair Value / Current Price)1/5 − 1. Assumes fair value is reached in exactly 5 years — a mechanical estimate only.

Data Sources & Limitations
Financial statements sourced from public filings. Prices updated daily. Forward assumptions are AI-generated. All monetary values in USD millions. Non-US ADR companies may have currency conversion inaccuracies. Models are point-in-time and do not update intra-quarter or account for M&A, macro shocks, or extraordinary items.

⚠️ Important Disclaimers — Please read without fail.

Investment Risk:
Investing in securities, including US equities and ETFs, involves inherent risks including the potential loss of principal. All investments are subject to market fluctuations, economic conditions, regulatory changes, and other factors that may affect their value. Past performance is not indicative of future results. This analysis is provided for informational and educational purposes only and should not be construed as investment advice under any circumstances.

No Investment Recommendation:
This analysis does not constitute, nor should it be interpreted as, an offer, solicitation, or recommendation to buy, sell, or hold any securities or financial products. Investors are strongly advised to conduct their own independent research and due diligence and to consult with a licensed financial advisor or an SEC-registered investment adviser before making any investment decisions, taking into account their individual financial situation, risk tolerance, and investment objectives.

Not SEC-Registered:
Finmagine is not registered as an investment adviser with the U.S. Securities and Exchange Commission (SEC) or any state securities authority. Nothing on this platform constitutes investment advice as defined under the Investment Advisers Act of 1940.

Conflict of Interest Disclosure:
The author and/or analyst may currently hold or have previously held positions in the securities discussed. Any such positions are not intended to influence the objectivity or independence of the analysis. This research is produced independently and is not sponsored, endorsed, or commissioned by any company or institution.

Information Sources:
The analysis is based on publicly available information including SEC filings (10-K, 10-Q), annual reports, management commentary, and publicly available financial data. Information is believed to be accurate as of the date of publication but may be subject to change without notice. Readers are encouraged to independently verify all information before acting upon it.

Forward-Looking Statements:
This analysis may contain forward-looking statements, forecasts, or projections that are inherently subject to risks, uncertainties, and assumptions. Actual results may differ materially from those expressed or implied. Finmagine does not undertake any obligation to update such statements in the future.

Limitation of Liability:
The content is provided "as is" without any warranties, express or implied. Finmagine expressly disclaims any liability for errors, omissions, or any losses incurred as a result of reliance on the information provided. Readers assume full responsibility for their investment decisions.